Found 51 results
Filters: Author is Seaman, Michael S  [Clear All Filters]
Halper-Stromberg A, Lu C-L, Klein F, Horwitz JA, Bournazos S, Nogueira L, Eisenreich TR, Liu C, Gazumyan A, Schaefer U et al..  2014.  Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice.. Cell.
Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV.  2014.  Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity.. Cell. 158(6):1243-53.
Falkowska E, Le KM, Ramos A, Doores KJ, Lee J H, Blattner C, Ramirez A, Derking R, van Gils MJ, Liang C-H et al..  2014.  Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers.. Immunity. 40(5):657-68.
Klein F, Nogueira L, Nishimura Y, Phad G, West AP, Halper-Stromberg A, Horwitz JA, Gazumyan A, Liu C, Eisenreich TR et al..  2014.  Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.. J Exp Med. 211(12):2361-72.
Sok D, Doores KJ, Briney B, Le KM, Saye-Francisco KL, Ramos A, Kulp DW, Julien J-P, Menis S, Wickramasinghe L et al..  2014.  Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV.. Sci Transl Med. 6(236):236ra63.
Sok D, van Gils MJ, Pauthner M, Julien J-P, Saye-Francisco KL, Hsueh J, Briney B, Lee J H, Le KM, Lee PS et al..  2014.  Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex.. Proc Natl Acad Sci U S A. 111(49):17624-9.
Gavrilyuk J, Ban H, Uehara H, Sirk SJ, Saye-Francisco K, Cuevas A, Zablowsky E, Oza A, Seaman MS, Burton DR et al..  2013.  Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG.. J Virol. 87(9):4985-93.
Ferguson AL, Falkowska E, Walker LM, Seaman MS, Burton DR, Chakraborty AK.  2013.  Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity data.. PLoS One. 8(12):e80562.
Sok D, Laserson U, Laserson J, Liu Y, Vigneault F, Julien J-P, Briney B, Ramos A, Saye KF, Le K et al..  2013.  The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies.. PLoS Pathog. 9(11):e1003754.
Horwitz JA, Halper-Stromberg A, Mouquet H, Gitlin AD, Tretiakova A, Eisenreich TR, Malbec M, Gravemann S, Billerbeck E, Dorner M et al..  2013.  HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice.. Proc Natl Acad Sci U S A.
Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, Liu J, Abbink P, Maxfield LF, Seaman MS et al..  2013.  Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys.. Cell. 155(3):531-9.
Diskin R, Klein F, Horwitz JA, Halper-Stromberg A, Sather ND, Marcovecchio PM, Lee T, West AP, Gao H, Seaman MS et al..  2013.  Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies.. J Exp Med. 210(6):1235-49.
Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, Pancera M, Zhou T, Incesu R-B, Fu BZhongzheng et al..  2013.  Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization.. Cell. 153(1):126-38.
Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang H-W, Shekhar K, Gupta S et al..  2013.  Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.. Nature.
Klein F, Gaebler C, Mouquet H, Sather ND, Lehmann C, Scheid JF, Kraft Z, Liu Y, Pietzsch J, Hurley A et al..  2012.  Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein.. J Exp Med. 209(8):1469-79.
Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, Scheid JF, Halper-Stromberg A, Gnanapragasam PNP, Spencer DIR, Seaman MS et al..  2012.  Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies.. Proc Natl Acad Sci U S A. 109(47):E3268-77.
Mouquet H, Warncke M, Scheid JF, Seaman MS, Nussenzweig MC.  2012.  Enhanced HIV-1 neutralization by antibody heteroligation.. Proc Natl Acad Sci U S A. 109(3):875-80.
Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, Mouquet H, Spatz LA, Diskin R, Abadir A et al..  2012.  HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.. Nature.
Kovacs JM, Nkolola JP, Peng H, Cheung A, Perry J, Miller CA, Seaman MS, Barouch DH, Chen B.  2012.  HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.. Proc Natl Acad Sci U S A. 109(30):12111-6.
Falkowska E, Ramos A, Feng Y, Zhou T, Moquin S, Walker LM, Wu X, Seaman MS, Wrin T, Kwong PD et al..  2012.  PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.. J Virol. 86(8):4394-403.
Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro JM, Sanmiguel A, Seaman MS, Ferrari G et al..  2012.  Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.. Nature. 482(7383):89-93.